A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
We're very excited to be returning to @Substack after 3 great years of doing our live nightly show, System Update, on @rumblevideo.
I'm particularly happy to be getting back to written reporting and long investigations. We'll have our first up today.
https://t.co/XPhI354NA4
We are closing to raising $70,000 to help HBCU students clear financial holds on their accounts so they can graduate in a few weeks. Our goal is $80,000, which is what we raised last Spring to help more than two dozen students cross the stage.
https://t.co/4irraNTHcx
We are honored to be highlighted among the top healthcare #AI collaboration trends of 2025, showing the power of multi-institution #oncology#research: https://t.co/pmH47BgA9J #BreastCancer@carisls "As a survivor, I approached this research with personal interest”@MarvaBailer
Did you know NIH and NCI funding ended on 1/30? #ClinicalTrials depend on stable NIH/NCI support. Contact your representatives today and urge full-year NIH funding: https://t.co/YbcwEYq10b #CancerResearch
On this date (and tomorrow’s) in 2016, #Snowzilla hit the DC area
We’ll see what the weekend brings, but apparently, Mother Nature is feeling snow-stalgic!
Share your #Snowzilla photos and memories here…
Now Enrolling: EA1241 Study of Breast Cancer Recurrence in Patients Who Participated in the TAILORx and RxPONDER Treatment Trials https://t.co/dJvpVBcFXk
ECOG-ACRIN & @CarisLS partner to train #AI models on data from 4k+ TAILORx trial cases, outperforming current tools to predict recurrence risk in early-stage #breastcancer. A big win for our public-private partnership & personalized care progress! https://t.co/04f6GoJPDD
In our August newsletter, the co-chairs spotlight an open letter to Congress from the National Clinical Trials Network Cooperative Group Chairs, detailing its significant contributions to patient welfare. Read their editorial and the full letter here: https://t.co/YijQElKu3w
Today, the U.S. Senate Committee on Appropriations considered and approved its draft FY26 appropriations bill that includes increases for:
✅ @NIH
✅ Federal #CancerResearch funding at @theNCI
✅ @CDC_Cancer
Read the full statement: https://t.co/MUhfwwWB6p (1/2)
Stop!
Please stop everything you are doing right now and read below super-important message from ECOG-ACRIN chairs- Drs. O’Dwyer and Schnall!
If we lose public support for pivotal NCI coop group research and it needs to stop- resuscitating it will be very hard or impossible…
We cannot let our cancer researchers’ work- and more importantly the promise their work holds for our patients to get lost!
Please share their message and support our mutual cause any way you can!
@ASCO #lcsm @eaonc